
Indigo BioAutomation transforms lab operations by building collaborative tools and leveraging big data insights to guide analysis and drive actionable solutions. Their leading-edge SaaS software technologies, including ASCENT for LC GC MS and ARQ for PCR, improve the speed and quality of laboratory data in various industries. The company utilizes machine learning, artificial intelligence, and domain expertise to create perceptive software, aiming to improve human health through the interpretation of molecular measurements. Indigo focuses on a data-centric approach, providing access to raw data for effective decision-making, moving beyond inefficient PDF and spreadsheet workflows. They specialize in automation, big data analysis, and advanced algorithms for high-throughput laboratory environments.

Indigo BioAutomation transforms lab operations by building collaborative tools and leveraging big data insights to guide analysis and drive actionable solutions. Their leading-edge SaaS software technologies, including ASCENT for LC GC MS and ARQ for PCR, improve the speed and quality of laboratory data in various industries. The company utilizes machine learning, artificial intelligence, and domain expertise to create perceptive software, aiming to improve human health through the interpretation of molecular measurements. Indigo focuses on a data-centric approach, providing access to raw data for effective decision-making, moving beyond inefficient PDF and spreadsheet workflows. They specialize in automation, big data analysis, and advanced algorithms for high-throughput laboratory environments.
Location: Carmel, Indiana
Core product: ASCENT (chromatography/mass spec) and ARQ (PCR) — cloud SaaS for lab data automation & analytics
Tech focus: Machine learning / AI for laboratory data, automation, and big-data analysis
Founded: 2006
Approx. employees: 43
Automation and analysis of high-throughput laboratory data for clinical and life-science applications.
2006
Biotechnology
“Bootstrap Incubation listed as an investor and lead on a Series B”